Business
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies
CARE currently cooperates with 19 health insurance companies in Germany in the field of colorectal cancer screening BERKELEY, Calif. and MAINZ, Germany, July
About this update from Quantum Cyber N.v.
[{"type":"text","content":"CARE currently cooperates with 19 health insurance companies in Germany in the field of colorectal cancer screening\nBERKELEY, Calif. and MAINZ, Germany, July 23, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), a diagnostics company specializing in the early detection of cancer, today announced a collaboration with CARE diagnostica Laborreagenzien GmbH (“CARE”). CARE is currently working with more than 15 statutory health insurance companies as part of special online-based screening concepts based on the widely used fecal immuniochemical test (FIT). Thanks to the cooperation with Mainz Biomed, the range of services for risk groups can now be expanded to include the ColoAlert® test, which uses molecular genetic analysis of biomarkers in stool using PCR to increase the detection rate, particularly in the early stages of the disease. The cooperation comes into effect immediately and supports Mainz Biomed in further expanding the distribution of ColoAlert® in the German market. It is in line with the growing demand for personalized screening solutions that focus on early intervention. Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information Please follow us to stay up to date:LinkedInX (Previously Twitter)FacebookAbout Mainz Biomed NVMainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe and the United Arab Emirates. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook. About CARE diagnostica Laborreagenzien GmbHCARE diagnostica Laborreagenzien GmbH stands for quality and pioneering decisions in the field of colorectal cancer screening in Germany for over 40 years. Further information can be found under carediag.de. For media inquiriesMC Services AGMax...